Inuvo Valuation

Is CD5N undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CD5N when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate CD5N's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate CD5N's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for CD5N?

Key metric: As CD5N is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for CD5N. This is calculated by dividing CD5N's market cap by their current revenue.
What is CD5N's PS Ratio?
PS Ratio0.5x
SalesUS$78.45m
Market CapUS$34.04m

Price to Sales Ratio vs Peers

How does CD5N's PS Ratio compare to its peers?

The above table shows the PS ratio for CD5N vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average1x
ISHA INTERSHOP Communications
0.7x5.9%€28.9m
LSX LS telcom
0.5x5.0%€20.3m
CLIQ Cliq Digital
0.08x13.2%€23.1m
TR9 OTRS
2.7x6.9%€32.0m
CD5N Inuvo
0.5x19.6%€34.0m

Price-To-Sales vs Peers: CD5N is good value based on its Price-To-Sales Ratio (0.5x) compared to the peer average (1x).


Price to Sales Ratio vs Industry

How does CD5N's PS Ratio compare vs other companies in the DE Software Industry?

8 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.2.2x10.6%
CD5N Inuvo
0.5x19.6%US$34.04m
CSH CENIT
0.3x5.2%US$72.32m
CLIQ Cliq Digital
0.08x13.2%US$24.22m
CD5N 0.5xIndustry Avg. 2.2xNo. of Companies7PS02.44.87.29.612+
8 CompaniesEstimated GrowthMarket Cap
Industry Avg.2.2x39.6%
CD5N Inuvo
0.5x62.4%US$34.04m
No more companies

Price-To-Sales vs Industry: CD5N is good value based on its Price-To-Sales Ratio (0.5x) compared to the German Software industry average (2.2x).


Price to Sales Ratio vs Fair Ratio

What is CD5N's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CD5N PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.5x
Fair PS Ratio2.7x

Price-To-Sales vs Fair Ratio: CD5N is good value based on its Price-To-Sales Ratio (0.5x) compared to the estimated Fair Price-To-Sales Ratio (2.7x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CD5N forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€0.22
€0.89
+303.5%
7.4%€0.94€0.80n/a3
Nov ’25€0.21
€0.87
+311.4%
7.4%€0.92€0.78n/a3
Oct ’25€0.22
€0.87
+294.6%
7.4%€0.92€0.78n/a3
Sep ’25€0.24
€0.87
+258.8%
7.4%€0.92€0.78n/a3
Aug ’25€0.27
€0.88
+228.6%
7.4%€0.93€0.79n/a3
Jul ’25€0.25
€0.88
+251.6%
7.4%€0.93€0.79n/a3
Jun ’25€0.24
€0.88
+269.2%
7.4%€0.93€0.79n/a3
May ’25€0.30
€0.88
+192.1%
7.4%€0.93€0.79n/a3
Apr ’25€0.34
€0.85
+145.9%
8.1%€0.91€0.78n/a2
Mar ’25€0.40
€0.85
+113.4%
8.1%€0.92€0.78n/a2
Feb ’25€0.39
€0.86
+119.4%
8.1%€0.93€0.79n/a2
Jan ’25€0.34
€0.86
+157.2%
8.1%€0.93€0.79n/a2
Dec ’24€0.26
€0.86
+229.9%
8.1%€0.93€0.79n/a2
Nov ’24€0.17
€0.69
+304.4%
33.3%€0.92€0.46€0.212
Oct ’24€0.19
€0.69
+263.7%
33.3%€0.92€0.46€0.222
Sep ’24€0.23
€0.69
+201.5%
33.3%€0.92€0.46€0.242
Aug ’24€0.22
€0.69
+214.3%
33.3%€0.91€0.46€0.272
Jul ’24€0.23
€0.69
+200.5%
33.3%€0.91€0.46€0.252
Nov ’23€0.37
€1.39
+277.7%
9.1%€1.52€1.27€0.172

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies